leadf
logo-loader
viewTRACON Pharmaceuticals

Proactive virtual event to showcase four rising stars of the life sciences industry

TRACON Pharmaceuticals, Helix BioPharma, Tetra Bio-Pharma and MediPharm Labs are among the standouts presenting at the investor-focused event

TRACON Pharmaceuticals - Proactive virtual event showcases four rising stars of the life sciences industry
The event will feature live webcast presentations from companies based in the US and Canada

Proactive, a digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American virtual investor conference.

The event will feature live webcast presentations from companies based in the US and Canada. Delegates will also be given the opportunity to put their questions to the presenters.

Joining Proactive’s One2One Investor Forum at 1 pm EST on June 23 are:

  • Charles Theuer, chief executive of TRACON Pharma (NASDAQ:TCON)
  • Heman Chao, CEO of Helix BioPharma (TSE:HBP) (OTCMKTS:HBPCF)
  • Guy Chamberland, CEO of Tetra Bio-Pharma (CVE:TBP)
  • Pat McCutcheon, CEO of MediPharm Labs (TSE:LABS)

“Proactive is at the forefront of bringing growth companies and investors together digitally," Proactive CEO Ian Mclelland in a statement.

“Our Virtual One2One, an online variant of the popular conference format we’ve run for more than a decade, is a yet another innovative way we are enabling communication between motivated private shareholders and some of the US and Canada’s most innovative businesses.”

Proactive is one of the fastest-growing financial media portals in the world, providing breaking news and analysis on companies across the globe. News coverage takes place around the clock via six offices on three continents. Proactive regularly organize large investor events in London, New York, and Sydney.

To book a future event, contact John Joyce on [email protected] For press queries call Ian Lyall on +44 7739 717 275.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: TRACON Pharmaceuticals

Price: 5.01 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $66.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the FDA has given the go-ahead for its human trial of envafolimab for sarcoma cancer. Theuer says it expects to start enrolling patients in the trial at 25 sites in the US in the fourth quarter of 2020.

on 08/18/2020

2 min read